Carboxypeptidase A6 suppresses the proliferation and invasion of colorectal cancer cells and is negatively regulated by miR-96–3p

2020, Erratum: global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA A Cancer J. Clin., 70, 313, 10.3322/caac.21609 Nowicki, 2018, Incidence, morbidity and 5-year survival of colorectal cancer patients in the Kujawsko-Pomorskie voivodship in 2005-2011, based on data from the National Health Fund, Pol. Przegl. Chir., 90, 1, 10.5604/01.3001.0011.8175 Micu, 2020, Evaluation of prognostic factors for 5 year-survival after surgery for colorectal cancer, Ann. Ital. Chir., 91, 41 Lyons, 2008, Characterization of carboxypeptidase A6, an extracellular matrix peptidase, J. Biol. Chem., 283, 7054, 10.1074/jbc.M707680200 Wei, 2002, Identification and characterization of three members of the human metallocarboxypeptidase gene family, J. Biol. Chem., 277, 14954, 10.1074/jbc.M112254200 Pizzuti, 2002, A peptidase gene in chromosome 8q is disrupted by a balanced translocation in a duane syndrome patient, Invest. Ophthalmol. Vis. Sci., 43, 3609 Sapio, 2012, Naturally occurring carboxypeptidase A6 mutations: effect on enzyme function and association with epilepsy, J. Biol. Chem., 287, 42900, 10.1074/jbc.M112.414094 Sapio, 2015, Novel carboxypeptidase A6 (CPA6) mutations identified in patients with juvenile myoclonic and generalized epilepsy, PLoS One, 10, 10.1371/journal.pone.0123180 Huang, 2019, Carboxypeptidase A6 promotes the proliferation and migration of hepatocellular carcinoma by up-regulating AKT signaling pathway, Curr Med Sci, 39, 727, 10.1007/s11596-019-2098-z Wang, 2020, Carboxypeptidase A6 was identified and validated as a novel potential biomarker for predicting the occurrence of active ulcerative colitis, J. Cell Mol. Med., 24, 8803, 10.1111/jcmm.15517 Ebert, 2012, Roles for microRNAs in conferring robustness to biological processes, Cell, 149, 515, 10.1016/j.cell.2012.04.005 Shao, 2019, LncRNA STXBP5-AS1 suppressed cervical cancer progression via targeting miR-96-5p/PTEN axis, Biomed. Pharmacother., 117, 10.1016/j.biopha.2019.109082 Liu, 2019, miR-96-5p promotes the proliferation and migration of ovarian cancer cells by suppressing Caveolae 1, J. Ovarian Res., 12, 57, 10.1186/s13048-019-0533-1 Yue, 2020, microRNA-96 promotes occurrence and progression of colorectal cancer via regulation of the AMPKalpha2-FTO-m6A/MYC axis, J. Exp. Clin. Cancer Res., 39, 240, 10.1186/s13046-020-01731-7 Ge, 2020, Inhibition of miR-96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1, Exp. Ther. Med., 20, 2134 Brunet Vega, 2013, microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers, Oncol. Rep., 30, 320, 10.3892/or.2013.2475 Manning, 2017, AKT/PKB signaling: navigating the network, Cell, 169, 381, 10.1016/j.cell.2017.04.001 Cheon, 2011, Mouse models of cancer, Annu. Rev. Pathol., 6, 95, 10.1146/annurev.pathol.3.121806.154244 Shariati, 2019, Targeting AKT for cancer therapy, Expet Opin. Invest. Drugs, 28, 977, 10.1080/13543784.2019.1676726 Zhao, 2019, MicroRNA-96-3p promotes metastasis of papillary thyroid cancer through targeting SDHB, Cancer Cell Int., 19, 287, 10.1186/s12935-019-1003-y